- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
With shares of Gilead Sciences falling in Wednesday trading after reporting better-than-expected earnings, TheStreet senior columnist Adam Feuerstein breaks down what has investors spooked.
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
The debate raging among investors is more about Gilead's future when hepatitis C revenue declines because of few available patients, greater-than-expected discounting and more competition.
An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.
Gilead Sciences reports fourth-quarter and 2014 earnings on Tuesday after the market close.
The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
New trial data from a group of hepatitis C patients treated with a higher dose of RG-101 are expected in early February, according to Regulus
The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.